<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/1999/REC-html401-19991224/loose.dtd">
<html><head><title>Report for pre-no_benefit 1440013933308 [GSEA]</title><link href='xtools.css' rel='stylesheet'><link href='http://www.broadinstitute.org/gsea/images/XBench.gif' rel='shortcut icon'></head><body><div class='richTable'><table cols='11' border='1'><th class='richTable'></th><th class='richTable'>GS<br> follow link to MSigDB</th><th class='richTable'>GS DETAILS</th><th class='richTable'>SIZE</th><th class='richTable'>ES</th><th class='richTable'>NES</th><th class='richTable'>NOM p-val</th><th class='richTable'>FDR q-val</th><th class='richTable'>FWER p-val</th><th class='richTable'>RANK AT MAX</th><th class='richTable'>LEADING EDGE</th><tr><td class='lessen'>1</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MYOGENESIS'>HALLMARK_MYOGENESIS</a></td><td><a href='HALLMARK_MYOGENESIS.html'>Details ...</a></td><td>118</td><td>-0.45</td><td>-1.96</td><td>0.000</td><td>0.001</td><td>0.001</td><td>3264</td><td>tags=47%, list=23%, signal=60%</td></tr><tr><td class='lessen'>2</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION'>HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION</a></td><td><a href='HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION.html'>Details ...</a></td><td>158</td><td>-0.43</td><td>-1.92</td><td>0.000</td><td>0.001</td><td>0.002</td><td>2188</td><td>tags=38%, list=16%, signal=45%</td></tr><tr><td class='lessen'>3</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_ANGIOGENESIS'>HALLMARK_ANGIOGENESIS</a></td><td><a href='HALLMARK_ANGIOGENESIS.html'>Details ...</a></td><td>25</td><td>-0.49</td><td>-1.60</td><td>0.015</td><td>0.032</td><td>0.173</td><td>1538</td><td>tags=24%, list=11%, signal=27%</td></tr><tr><td class='lessen'>4</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_WNT_BETA_CATENIN_SIGNALING'>HALLMARK_WNT_BETA_CATENIN_SIGNALING</a></td><td><a href='HALLMARK_WNT_BETA_CATENIN_SIGNALING.html'>Details ...</a></td><td>35</td><td>-0.46</td><td>-1.60</td><td>0.018</td><td>0.024</td><td>0.176</td><td>1640</td><td>tags=26%, list=12%, signal=29%</td></tr><tr><td class='lessen'>5</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_IL6_JAK_STAT3_SIGNALING'>HALLMARK_IL6_JAK_STAT3_SIGNALING</a></td><td><a href='HALLMARK_IL6_JAK_STAT3_SIGNALING.html'>Details ...</a></td><td>65</td><td>-0.35</td><td>-1.36</td><td>0.065</td><td>0.191</td><td>0.853</td><td>3780</td><td>tags=42%, list=27%, signal=57%</td></tr><tr><td class='lessen'>6</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_NOTCH_SIGNALING'>HALLMARK_NOTCH_SIGNALING</a></td><td><a href='HALLMARK_NOTCH_SIGNALING.html'>Details ...</a></td><td>29</td><td>-0.40</td><td>-1.33</td><td>0.119</td><td>0.208</td><td>0.921</td><td>4365</td><td>tags=48%, list=31%, signal=70%</td></tr><tr><td class='lessen'>7</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MITOTIC_SPINDLE'>HALLMARK_MITOTIC_SPINDLE</a></td><td><a href='HALLMARK_MITOTIC_SPINDLE.html'>Details ...</a></td><td>196</td><td>-0.28</td><td>-1.32</td><td>0.032</td><td>0.191</td><td>0.931</td><td>3059</td><td>tags=28%, list=22%, signal=35%</td></tr><tr><td class='lessen'>8</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_ALLOGRAFT_REJECTION'>HALLMARK_ALLOGRAFT_REJECTION</a></td><td><a href='HALLMARK_ALLOGRAFT_REJECTION.html'>Details ...</a></td><td>137</td><td>-0.29</td><td>-1.27</td><td>0.073</td><td>0.237</td><td>0.976</td><td>4226</td><td>tags=41%, list=30%, signal=58%</td></tr><tr><td class='lessen'>9</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_UV_RESPONSE_DN'>HALLMARK_UV_RESPONSE_DN</a></td><td><a href='HALLMARK_UV_RESPONSE_DN.html'>Details ...</a></td><td>127</td><td>-0.28</td><td>-1.21</td><td>0.131</td><td>0.330</td><td>0.998</td><td>2910</td><td>tags=29%, list=21%, signal=36%</td></tr><tr><td class='lessen'>10</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_KRAS_SIGNALING_UP'>HALLMARK_KRAS_SIGNALING_UP</a></td><td><a href='HALLMARK_KRAS_SIGNALING_UP.html'>Details ...</a></td><td>141</td><td>-0.26</td><td>-1.14</td><td>0.221</td><td>0.469</td><td>1.000</td><td>3347</td><td>tags=31%, list=24%, signal=41%</td></tr><tr><td class='lessen'>11</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_APICAL_JUNCTION'>HALLMARK_APICAL_JUNCTION</a></td><td><a href='HALLMARK_APICAL_JUNCTION.html'>Details ...</a></td><td>136</td><td>-0.25</td><td>-1.11</td><td>0.257</td><td>0.500</td><td>1.000</td><td>3005</td><td>tags=34%, list=22%, signal=43%</td></tr><tr><td class='lessen'>12</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_TGF_BETA_SIGNALING'>HALLMARK_TGF_BETA_SIGNALING</a></td><td><a href='HALLMARK_TGF_BETA_SIGNALING.html'>Details ...</a></td><td>51</td><td>-0.29</td><td>-1.09</td><td>0.319</td><td>0.497</td><td>1.000</td><td>3723</td><td>tags=29%, list=27%, signal=40%</td></tr><tr><td class='lessen'>13</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_IL2_STAT5_SIGNALING'>HALLMARK_IL2_STAT5_SIGNALING</a></td><td><a href='HALLMARK_IL2_STAT5_SIGNALING.html'>Details ...</a></td><td>158</td><td>-0.22</td><td>-1.00</td><td>0.459</td><td>0.701</td><td>1.000</td><td>2182</td><td>tags=21%, list=16%, signal=24%</td></tr><tr><td class='lessen'>14</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_COAGULATION'>HALLMARK_COAGULATION</a></td><td><a href='HALLMARK_COAGULATION.html'>Details ...</a></td><td>84</td><td>-0.24</td><td>-0.98</td><td>0.494</td><td>0.709</td><td>1.000</td><td>4903</td><td>tags=48%, list=35%, signal=73%</td></tr><tr><td class='lessen'>15</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_COMPLEMENT'>HALLMARK_COMPLEMENT</a></td><td><a href='HALLMARK_COMPLEMENT.html'>Details ...</a></td><td>141</td><td>-0.22</td><td>-0.98</td><td>0.516</td><td>0.679</td><td>1.000</td><td>3272</td><td>tags=26%, list=23%, signal=34%</td></tr><tr><td class='lessen'>16</td><td><a href='http://cancerimmunity.org/peptide/overexpressed/'>CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS</a></td><td><a href='CANCER_IMMUNITY_ANTIGENS_OVEREXPRESSED_IN_TUMORS.html'>Details ...</a></td><td>27</td><td>-0.27</td><td>-0.88</td><td>0.647</td><td>0.873</td><td>1.000</td><td>2676</td><td>tags=30%, list=19%, signal=37%</td></tr><tr><td class='lessen'>17</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_MYC_TARGETS_V2'>HALLMARK_MYC_TARGETS_V2</a></td><td><a href='HALLMARK_MYC_TARGETS_V2.html'>Details ...</a></td><td>58</td><td>-0.21</td><td>-0.81</td><td>0.800</td><td>0.973</td><td>1.000</td><td>2693</td><td>tags=21%, list=19%, signal=26%</td></tr><tr><td class='lessen'>18</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_APICAL_SURFACE'>HALLMARK_APICAL_SURFACE</a></td><td><a href='HALLMARK_APICAL_SURFACE.html'>Details ...</a></td><td>29</td><td>-0.24</td><td>-0.80</td><td>0.780</td><td>0.942</td><td>1.000</td><td>2887</td><td>tags=28%, list=21%, signal=35%</td></tr><tr><td class='lessen'>19</td><td><a href='http://www.broadinstitute.org/gsea/msigdb/cards/HALLMARK_HEDGEHOG_SIGNALING'>HALLMARK_HEDGEHOG_SIGNALING</a></td><td><a href='HALLMARK_HEDGEHOG_SIGNALING.html'>Details ...</a></td><td>24</td><td>-0.23</td><td>-0.72</td><td>0.866</td><td>0.996</td><td>1.000</td><td>3116</td><td>tags=33%, list=22%, signal=43%</td></tr><tr><td class='lessen'>20</td><td><a href='http://cancerimmunity.org/peptide/tumor-specific/'>CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS</a></td><td><a href='CANCER_IMMUNITY_SHARED_TUMOR_SPECIFIC_ANTIGENS.html'>Details ...</a></td><td>2</td><td>-0.40</td><td>-0.60</td><td>0.950</td><td>0.991</td><td>1.000</td><td>2341</td><td>tags=50%, list=17%, signal=60%</td></tr><caption class='table'>Table: Gene sets enriched in phenotype <b>pre-no_benefit (5 samples)<b>&nbsp<a href='gsea_report_for_pre-no_benefit_1440013933308.xls'>[plain text format]</a></caption></table></div><br></body></html>